Endovasc President & CEO Appears on the Wall Street Reporter
Tuesday August 1, 5:13 pm ET
HOUSTON--(BUSINESS WIRE)--Aug. 1, 2006--Endovasc Inc. (OTCBB: EVSC - News), announced that Dr. Diane Dottavio, the Company's President and CEO, appeared on the Wall Street Reporter to discuss its planned Phase IIIa clinical trials and the Company's diverse product pipeline.
ADVERTISEMENT
click here
The interview can be heard on www.wallstreetreporter.com.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor:
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Endovasc's Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-KSB, and quarterly reports on Form 10-QSB.
Contact:
Endovasc, Inc.
Rob Johnson, 936-582-5920